The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
1
|
A | Alimentary tract and metabolism | |
2
|
A05 | Bile and liver therapy | |
3
|
A05A | Bile therapy | |
4
|
A05AA | Bile acid preparations | |
5
|
A05AA02 | Ursodeoxycholic acid |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Code | Route | Amount | Notes |
|---|---|---|---|
| ORAL | Oral | 750 mg |
| Active Ingredient |
|---|
|
The ursodeoxycholic acid converts lithogenic bile in non-lithogenic bile and gradually dissolves the cholesterol gallstones. |
| Document | Type | Information Source | |
|---|---|---|---|
| ACTIGALL Capsule | MPI, US: SPL/Old | FDA, National Drug Code (US) | |
| CHOLURSO Film-coated tablet | MPI, EU: SmPC | Health Products Regulatory Authority (IE) | |
| PROURSAN Capsule, hard | MPI, EU: SmPC | Health Products Regulatory Authority (IE) | |
| URSO 250 / FORTE Film-coated tablet | MPI, US: SPL/PLR | FDA, National Drug Code (US) | |
| URSOFALK Capsule, hard | MPI, EU: SmPC | Medicines & Healthcare Products Regulatory Agency (GB) | |
| URSOGRIX Capsule, hard | MPI, EU: SmPC | Health Products Regulatory Authority (IE) |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.